A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy Journal Article
| Authors: | Hurria, A.; Zuckerman, E.; Panageas, K. S.; Fornier, M.; D'Andrea, G.; Dang, C.; Moasser, M.; Robson, M.; Seidman, A.; Currie, V.; VanPoznak, C.; Theodoulou, M.; Lachs, M. S.; Hudis, C. |
| Article Title: | A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy |
| Abstract: | OBJECTIVES: To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL). DESIGN: A geriatric assessment measuring functional status, comorbidity, mood, nutritional status, and QOL was performed before chemotherapy, at the end of chemotherapy, and 6 months later. SETTING: This prospective longitudinal study was conducted at Memorial Sloan-Kettering Cancer Center, New York, New York. PARTICIPANTS: Fifty patients aged 65 and older with Stage I to III breast cancer receiving any adjuvant chemotherapy; 49 were evaluable. MEASUREMENTS: The chemotherapy regimen and the toxicity to chemotherapy were recorded. A geriatric assessment was performed before the start of chemotherapy, on completion of chemotherapy, and 6 months after completion of chemotherapy. QOL testing was performed at the same times. RESULTS: Patients (mean age 68, range 65-84) received an anthracycline-based chemotherapy regimen (n = 15) or cyclophosphamide 600 mg/m 2 intravenously (IV), methotrexate 40 mg/m 2 IV, 5-fluorouracil 600 mg/m 2 IV every 3 weeks for eight cycles (n = 34). Grade 3 or 4 toxicity occurred in 53% (n = 26), hematological toxicity in 27% (n = 13), and nonhematological toxicity in 31% (n = 15). Despite toxicity, there was no significant longitudinal change in functional status or QOL. CONCLUSION: Despite toxicity from adjuvant chemotherapy, this cohort of relatively young older patients maintained their functional status and QOL from before chemotherapy to 6 months postchemotherapy. Subtle changes in higher-order functioning would require assessment using different geriatric assessment tools. © 2006, Copyright the Authors. |
| Keywords: | aged; aged, 80 and over; functional assessment; major clinical study; fatigue; neutropenia; fluorouracil; diarrhea; hypertension; cancer adjuvant therapy; chemotherapy, adjuvant; methotrexate; prospective study; prospective studies; nutritional status; quality of life; infection; breast cancer; mastectomy; blood toxicity; neuropathy; antineoplastic combined chemotherapy protocols; cyclophosphamide; breast neoplasms; time factors; arthralgia; mood; adjuvant chemotherapy; thrombosis; comorbidity; anthracycline derivative; toxicity; functional status; mastectomy, segmental; heart muscle ischemia; cerebrovascular accident; health status indicators; longitudinal study; geriatric assessment; vertigo; gastritis |
| Journal Title: | Journal of the American Geriatrics Society |
| Volume: | 54 |
| Issue: | 7 |
| ISSN: | 0002-8614 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2006-07-01 |
| Start Page: | 1119 |
| End Page: | 1124 |
| Language: | English |
| DOI: | 10.1111/j.1532-5415.2006.00789.x |
| PUBMED: | 16866685 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 35" - "Export Date: 4 June 2012" - "CODEN: JAGSA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work